¿El efecto cardio- y nefroprotector de la canagliflocina beneficia exclusivamente a población en prevención secundaria (PS) o se extiende también a pacientes en prevención primaria (PP)?
Read
3589
Timeswas read the article
2207
Total PDF
1382
Total HTML
Article information
ISSN: 18889700Original language: Spanish
The statistics are updated each day
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 July | 21 | 18 | 39 |
| 2024 June | 49 | 43 | 92 |
| 2024 May | 40 | 38 | 78 |
| 2024 April | 48 | 26 | 74 |
| 2024 March | 35 | 30 | 65 |
| 2024 February | 39 | 28 | 67 |
| 2024 January | 30 | 33 | 63 |
| 2023 December | 21 | 21 | 42 |
| 2023 November | 26 | 24 | 50 |
| 2023 October | 47 | 40 | 87 |
| 2023 September | 26 | 34 | 60 |
| 2023 August | 32 | 33 | 65 |
| 2023 July | 34 | 40 | 74 |
| 2023 June | 40 | 27 | 67 |
| 2023 May | 37 | 41 | 78 |
| 2023 April | 23 | 31 | 54 |
| 2023 March | 23 | 27 | 50 |
| 2023 February | 19 | 36 | 55 |
| 2023 January | 26 | 41 | 67 |
| 2022 December | 36 | 36 | 72 |
| 2022 November | 31 | 37 | 68 |
| 2022 October | 25 | 39 | 64 |
| 2022 September | 30 | 33 | 63 |
| 2022 August | 29 | 49 | 78 |
| 2022 July | 32 | 55 | 87 |
| 2022 June | 33 | 45 | 78 |
| 2022 May | 36 | 42 | 78 |
| 2022 April | 33 | 59 | 92 |
| 2022 March | 42 | 72 | 114 |
| 2022 February | 31 | 75 | 106 |
| 2022 January | 41 | 90 | 131 |
| 2021 December | 32 | 63 | 95 |
| 2021 November | 28 | 41 | 69 |
| 2021 October | 36 | 88 | 124 |
| 2021 September | 27 | 62 | 89 |
| 2021 August | 18 | 53 | 71 |
| 2021 July | 21 | 60 | 81 |
| 2021 June | 16 | 43 | 59 |
| 2021 May | 25 | 95 | 120 |
| 2021 April | 35 | 139 | 174 |
| 2021 March | 33 | 70 | 103 |
| 2021 February | 24 | 68 | 92 |
| 2021 January | 23 | 52 | 75 |
| 2020 December | 37 | 77 | 114 |
| 2020 November | 9 | 41 | 50 |
| 2020 October | 3 | 12 | 15 |
Show all
